Department of Gastroenterological Surgery, Kochi Health Sciences Center, 2125-1 Ike, Kochi City, Kochi, 781-1555, Japan.
Department of Surgery, Dokkyo Medical University Hospital, Tochigi, Japan.
Langenbecks Arch Surg. 2021 May;406(3):667-677. doi: 10.1007/s00423-021-02167-z. Epub 2021 Apr 14.
The aim of this study was to validate and improve the 8th edition of the Union for International Cancer Control (UICC) staging system for pancreatic ductal adenocarcinoma (PDAC).
Prognostic impact of the pathological tumor (pT) and lymph node (pN) stages between the 7th and 8th editions were compared using a single-center cohort of 311 patients who underwent curative pancreatic resection for PDAC.
Applying the 7th edition T staging system resulted in a clustering of pT3 cases (92.3%) and failed to show significant prognostic differences between the three pT stages. However, applying the 8th edition T staging system yielded a more even distribution and resulted in an excellent prognostic separation between the pT stages based on decreases in median survival (month [pT1: 69.4, pT2: 27.6, pT3: 16.7], p=0.001). In pN staging system, the 8th edition provided more precise prognostication in median survival (month [pN0: 41.7, pN1: 25.6, pN2: 14.4], p<0.001). Moreover, in the 8th edition pT2 category, patients with portal vein invasion (PVI) showed significantly worse survival than those without PVI (median survival months [without PVI: 38.2, with PVI: 17.1], p<0.001).
The 8th edition provides a more even distribution among stages and better stage discriminations compared to the 7th edition. The 8th edition pT2 category should be subdivided according to PVI status of the patient to allow for more precise patient prognostication.
本研究旨在验证和改进国际抗癌联盟(UICC)第 8 版用于胰腺导管腺癌(PDAC)的分期系统。
通过单中心 311 例接受根治性胰腺切除术治疗 PDAC 的患者队列,比较第 7 版和第 8 版病理肿瘤(pT)和淋巴结(pN)分期的预后影响。
应用第 7 版 T 分期系统导致 pT3 病例(92.3%)聚类,并且三个 pT 分期之间未能显示出显著的预后差异。然而,应用第 8 版 T 分期系统导致更均匀的分布,并基于中位生存期的降低,在 pT 分期之间产生了极好的预后分离(月[pT1:69.4,pT2:27.6,pT3:16.7],p=0.001)。在 pN 分期系统中,第 8 版在中位生存期方面提供了更准确的预后预测(月[pN0:41.7,pN1:25.6,pN2:14.4],p<0.001)。此外,在第 8 版 pT2 类别中,门静脉侵犯(PVI)的患者的生存情况明显比没有 PVI 的患者差(中位生存月数[无 PVI:38.2,有 PVI:17.1],p<0.001)。
与第 7 版相比,第 8 版在分期之间提供了更均匀的分布和更好的分期区分。第 8 版 pT2 类别应根据患者的 PVI 状况进行细分,以实现更精确的患者预后预测。